79 filings
Page 3 of 4
8-K
ljp8r8
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
8-K
ikj9 8z9uk3ez
11 May 22
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
9:00am
S-8
nsr5bt7u8qkabey0xuzr
21 Apr 22
Registration of securities for employees
6:52pm
8-K
e0wcz839jwka z3oc
1 Apr 22
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
7:34am
8-K
t2lwfeogv 7bv0y
11 Feb 22
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
8:00am
8-K
156ce1v6 4fwr92tdb
5 Jan 22
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen
10:00am
8-K
ib6wm5ow1h39o3
3 Jan 22
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
2:22pm
8-K
ex1yfiq hnrv7lcli
16 Nov 21
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
bjpaif5j0xbw4y4ntbc
12 Nov 21
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
8:15am
DEFA14A
sv10c 99ayfrlle8x
22 Sep 21
Additional proxy soliciting materials
5:07pm
DEF 14A
hy3zn
22 Sep 21
Definitive proxy
4:48pm
10-K
k7hummi8 zr7
22 Sep 21
Annual report
4:45pm
8-K
htw42k8 9nw
22 Sep 21
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
4:38pm
10-Q
mn083qtm0u24jr4n
21 Jun 21
Quarterly report
5:06pm
424B4
whf4s9n8
10 May 21
Prospectus supplement with pricing info
4:52pm
EFFECT
u3n9h1s
7 May 21
Notice of effectiveness
12:15am
CERT
w2psig
7 May 21
Certification of approval for exchange listing
12:00am